DRDO’s anti-Covid drug will be rolled out on 11-12 May

New Delhi,9/5 (AO Bureau);DRDO’s anti-covid drug ‘2-deoxy-D-glucose’ has recently been approved by DCGI for emergency use. Dr. Satish Reddy, Chairman of DRDO has said that from 11 or 12 May this anti-covid drug will start becoming available in the market. He has told that initially at least 10 thousand doses of medicine can come in the market. He made this claim in a program of India TV. Clearly, this information can be very useful for fighting Corona, and you should know it.

DRDO chairman G Sathish Reddy said, “This drug made by DRDO and Dr Reddy Lab has been approved by DCGI. Consumption of this drug will relieve oxygen dependent oxygen support in 2-3 days. He will recover soon. This medicine will soon be available in hospitals. ” However, he also said that patients should take this medicine only on the basis of the advice of the doctor.

Clinical tests have shown that this drug helps in rapid recovery of hospitalized patients and reduces dependence on oxygen delivery from outside. RT-PCR negative conversion has been observed in the treatment of overdose covid patients with 2-DG. This medicine will be very beneficial for the people suffering from Kovid.

When and when did the 2-DG trial take place
Let us tell you, during the first wave of epidemic in April 2020, INMAS-DRDO scientists conducted laboratory tests with the help of Center for Cellular and Molecular Biology (CCMB), Hyderabad. They found that this drug works effectively against SARS-COV-2 virus and prevents viral growth. Based on these results, the Drugs Controller General of India (DCGI) Central Drugs Standard Control Organization (CDSCO) in May 2020 allowed a 2-DG phase-2 clinical trial in Covid patients.

In Phase II trials conducted from May to October 2020, the drug was found safe in patients and showed significant improvement in their recovery. The second phase was conducted in six hospitals and Phase 2B clinical trials were conducted in 11 hospitals across the country. In Phase-2, 110 patients were tried.

Based on the successful results, DCGI allowed Phase-3 clinical trials in November 2020. Phase-3 clinical trials were conducted on 220 patients between December 2020 to March 2021 in 27 Kovid hospitals in Delhi, Uttar Pradesh, West Bengal, Gujarat, Rajasthan, Maharashtra, Andhra Pradesh, Telangana, Karnataka and Tamil Nadu. The data for the Phase III clinical trial were presented to DCGI. In the case of 2-DG, a significantly higher proportion of symptoms was seen in patients. By the third day, patients were relieved of supplemental oxygen dependence (42 per cent vs. 31 per cent), indicating early relief from oxygen therapy / dependence. A similar trend was seen in patients older than 65 years.

Comments are closed.